Literature DB >> 15046921

The targeting of anionized polyvinylpyrrolidone to the renal system.

Hiroshi Kodaira1, Yasuo Tsutsumi, Yasuo Yoshioka, Haruhiko Kamada, Yoshihisa Kaneda, Yoko Yamamoto, Shin-ichi Tsunoda, Takayuki Okamoto, Yohei Mukai, Hiroko Shibata, Shinsaku Nakagawa, Tadanori Mayumi.   

Abstract

We reported that the co-polymer composed of vinylpyrrolidone and maleic acid selectively distributed into the kidneys after i.v. injection. To further optimize the renal drug delivery system, we assessed the renal targeting capability of anionized polyvinylpyrrolidone (PVP) derivatives after intravenous administration in mice. The elimination of anionized PVP derivatives from the blood decreased with increasing anionic groups, and the clearance of carboxylated PVP and sulfonated PVP from the blood was almost similar. But carboxylated PVP efficiently accumulated in the kidney, whereas sulfonated PVP was rapidly excreted in the urine. The renal levels of carboxylated PVP were about five-fold higher than sulfonated PVP. Additionally, carboxylated PVP was effectively taken up by the renal proximal tubular epithelial cells in vivo after i.v. injection. These anionized PVP derivatives did not show any cytotoxicity against renal tubular cells and endothelial cells in vitro. Thus, these carboxylated and sulfonated PVPs may be useful polymeric carriers for drug delivery to the kidney and bladder, respectively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046921     DOI: 10.1016/j.biomaterials.2003.10.097

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  16 in total

Review 1.  Polymer architecture and drug delivery.

Authors:  Li Yan Qiu; You Han Bae
Journal:  Pharm Res       Date:  2006-01-11       Impact factor: 4.200

2.  Tumor-targeted HPMA copolymer-(RGDfK)-(CHX-A''-DTPA) conjugates show increased kidney accumulation.

Authors:  Mark P Borgman; Tomika Coleman; Rohit B Kolhatkar; Sandra Geyser-Stoops; Bruce R Line; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2008-07-18       Impact factor: 9.776

Review 3.  Current progress in nanotechnology applications for diagnosis and treatment of kidney diseases.

Authors:  Sue Hyun Lee; Jung Bok Lee; Min Soo Bae; Daniel A Balikov; Amy Hwang; Timothy C Boire; Il Keun Kwon; Hak-Joon Sung; Jae Won Yang
Journal:  Adv Healthc Mater       Date:  2015-06-29       Impact factor: 9.933

4.  Selective targeting and therapy of metastatic and multidrug resistant tumors using a long circulating podophyllotoxin nanoparticle.

Authors:  Aniruddha Roy; Yucheng Zhao; Yang Yang; Andras Szeitz; Tara Klassen; Shyh-Dar Li
Journal:  Biomaterials       Date:  2017-05-11       Impact factor: 12.479

Review 5.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

6.  Comparative biodistribution of PAMAM dendrimers and HPMA copolymers in ovarian-tumor-bearing mice.

Authors:  S Sadekar; A Ray; M Janàt-Amsbury; C M Peterson; H Ghandehari
Journal:  Biomacromolecules       Date:  2010-12-03       Impact factor: 6.988

7.  Dexamethasone prodrug treatment prevents nephritis in lupus-prone (NZB × NZW)F1 mice without causing systemic side effects.

Authors:  Fang Yuan; Richard K Nelson; Dana E Tabor; Yijia Zhang; Mohammed P Akhter; Karen A Gould; Dong Wang
Journal:  Arthritis Rheum       Date:  2012-12

8.  Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.

Authors:  Libin Zhang; Rui Zhang; Jiyuan Yang; Jiawei Wang; Jindřich Kopeček
Journal:  J Control Release       Date:  2016-06-04       Impact factor: 9.776

9.  Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.

Authors:  Xia-kai He; Zhi-xiang Yuan; Xiao-juan Wu; Chao-qun Xu; Wan-yu Li
Journal:  Theranostics       Date:  2012-11-06       Impact factor: 11.556

Review 10.  Kidney-targeted drug delivery systems.

Authors:  Peng Zhou; Xun Sun; Zhirong Zhang
Journal:  Acta Pharm Sin B       Date:  2014-01-23       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.